Please assess the completion status of the following clinical trial:

Trial Title: Trial of Exenatide for Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Parkinson's disease.~* Males or Females.~* Hoehn and Yahr stage ≤ 2.5 in the On medication state.~* Between 25 and 75 years of age.~* On dopaminergic treatment with wearing off phenomena.~* Ability to self-administer, or to arrange carer administration of trial drug.~* Documented informed consent to participate.~Exclusion Criteria:~* Diagnosis or suspicion of other cause for parkinsonism.~* Body mass index \<18.5.~* Known abnormality on CT or MRI brain imaging considered likely to compromise compliance with trial protocol/DaTSCAN acquisition.~* Concurrent dementia defined by a score lower than 120 on the Mattis Dementia Rating Scale.~* Concurrent severe depression defined by a score \>16 on the MADRS.~* Prior intra-cerebral surgical intervention for Parkinson's disease.~* Already actively participating in a trial of a device, drug or surgical treatment for Parkinson's disease.~* Severe gastrointestinal disease (e.g. gastroparesis).~* Previous exposure to Exenatide.~* Severely impaired renal function with creatinine clearance \<30ml/min.~* History of pancreatitis.~* Hyperlipidaemia.~* History or suspicion of thyroid cancer~* Known or suspected intolerance of DaTSCAN or Potassium Iodide administration.~* Females that are pregnant or breast feeding.~* Participants who lack the capacity to give informed consent~* Any medical or psychiatric condition which in the investigator's opinion compromises the potential participant's ability to participate.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: ACTIVE_COMPARATOR): Bydureon- 2mg administered subcutaneously once weekly
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, 2mg administered subcutaneously once weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).